Direct comparison of the acute subjective, emotional, autonomic, and endocrine effects of MDMA, methylphenidate, and modafinil in healthy subjects by Dolder, Patrick C. et al.
ORIGINAL INVESTIGATION
Direct comparison of the acute subjective, emotional, autonomic,
and endocrine effects of MDMA, methylphenidate, and modafinil
in healthy subjects
Patrick C. Dolder1 & Felix Müller2 & Yasmin Schmid1 & Stefan J. Borgwardt2 &
Matthias E. Liechti1
Received: 21 February 2017 /Accepted: 9 May 2017 /Published online: 27 May 2017
# The Author(s) 2017. This article is an open access publication
Abstract
Rationale 3,4-Methylenedioxymethamphetamine (MDMA)
is used recreationally and investigated as an adjunct to
psychotherapy. Methylphenidate and modafinil are
psychostimulants that are used to treat attention-deficit/hyper-
activity disorder and narcolepsy, respectively, but they are also
misused as cognitive enhancers. Little is known about differ-
ences in the acute effects of equally cardiostimulant doses of
these stimulant-type substances compared directly within the
same subjects.
Methods We investigated the acute autonomic, subjective, en-
docrine, and emotional effects of single doses of MDMA
(125 mg), methylphenidate (60 mg), modafinil (600 mg),
and placebo in a double-blind, cross-over study in 24 healthy
participants. Acute drug effects were tested using psychomet-
ric scales, the Facial Emotion Recognition Task (FERT), and
the Sexual Arousal and Desire Inventory (SADI).
Results All active drugs produced comparable hemodynamic
and adverse effects. MDMA produced greater increases in
pupil dilation, subjective good drug effects, drug liking, hap-
piness, trust, well-being, and alterations in consciousness than
methylphenidate or modafinil. Only MDMA reduced subjec-
tive anxiety and impaired fear recognition and led to misclas-
sifications of emotions as happy on the FERT. On the SADI,
only MDMA produced sexual arousal-like effects. Only
MDMA produced marked increases in cortisol, prolactin,
and oxytocin. In contrast to MDMA, methylphenidate in-
creased subjective anxiety, and methylphenidate and
modafinil increased misclassifications of emotions as angry
on the FERT. Modafinil had no significant subjective drug
effects but significant sympathomimetic and adverse effects.
Conclusions MDMA induced subjective, emotional, sexual,
and endocrine effects that were clearly distinct from those of
methylphenidate and modafinil at the doses used.
Keywords MDMA .Methylphenidate .Modafinil . Emotion
recognition . Sexual arousal
Introduction
3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) is
used recreationally and investigated as an adjunct to psycho-
therapy for patients with posttraumatic stress disorder
(Mithoefer et al. 2010; Oehen et al. 2013). Methylphenidate
and modafinil are stimulants that are used to treat attention-
deficit/hyperactivity disorder and narcolepsy, respectively, but
also misused as cognitive enhancers (Liakoni et al. 2015;
Maier et al. 2015; Maier et al. 2013; Repantis et al. 2010).
The neurotransmitter interaction profile of MDMA clearly
differs from classic psychostimulants (Liechti 2015).
MDMA releases serotonin and oxytocin (Francis et al. 2016;
Hysek et al. 2012c; Kirkpatrick et al. 2014b; Simmler et al.
2013), in contrast to psychostimulant amphetamines (Liechti
2015; Simmler et al. 2013) and related substances, such as
methylphenidate and modafinil, that enhance dopaminergic
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and noradrenergic neurotransmission without affecting sero-
tonin or oxytocin (Hannestad et al. 2010; Madras et al. 2006;
Qu et al. 2008; Schmeichel and Berridge 2013; Schmid et al.
2014; Simmler et al. 2014; Zolkowska et al. 2009). The main
goal of the present study was to characterize and compare the
effects of MDMAwith the stimulant-type substances methyl-
phenidate and modafinil at single relatively high doses
matched for their cardiostimulant properties (comparable
rate-pressure products; Hysek et al. 2014b; Jasinski 2000).
The acute effects of MDMA have been extensively studied
in healthy subjects (Dumont and Verkes 2006; Vizeli and
Liechti 2017) but only rarely compared directly with other
orally administered stimulant substances (Hysek et al.
2014b; Parrott et al. 2011; Schmid et al. 2014; Tancer and
Johanson 2003). MDMA induced greater Bempathogenic^
mood effects, including closeness to others, openness, trust,
happiness, and wanting to be with others, compared with oral
methylphenidate (Hysek et al. 2014a; Schmid et al. 2014).
MDMA, but not methylphenidate, impaired the recognition
of sad and fearful emotions on the Face Emotion
Recognition Task (FERT) and increased biomarkers of sero-
tonergic activity, including plasma concentrations of cortisol,
prolactin, and oxytocin (Bedi et al. 2010; Hysek et al. 2014a;
Kirkpatrick et al. 2014b; Kuypers et al. 2017; Schmid et al.
2014). In contrast, methylphenidate, but not MDMA, in-
creased subjective concentration (Hysek et al. 2014a;
Schmid et al. 2014) and sexual arousal that was elicited by
explicit visual sexual stimuli (Schmid et al. 2015b). MDMA
produced greater drug liking, elation, and good drug effects
than amphetamine (Tancer and Johanson 2003), whereas other
studies reported positive mood following methamphetamine
but not MDMA administration (Parrott et al. 2011). However,
these studies used only a few outcome measures and did not
comprehensively evaluate emotional drug effects. MDMA
may have unique empathogenic and prosocial effects that
are distinct from classic stimulants (Bedi et al. 2010;
Bershad et al. 2016; Hysek et al. 2014b; Kamilar-Britt and
Bedi 2015; Schmid et al. 2014), but these differences need
to be confirmed using blinded administration of MDMA and
different stimulants within the same subjects. Therefore, the
present cross-over study directly compared the subjective,
emotional, autonomic, sexual, and endocrine effects of
MDMA, methylphenidate, and modafinil. We expected
MDMA to produce acute effects that are distinct from those
of methylphenidate and modafinil. The a priori hypotheses
defined in the study protocol were that MDMA, but not meth-
ylphenidate or modafinil, at the doses used, will produce
prosocial and empathic feelings (closeness to others, open-
ness, trust, want to be with other people) and elevate plasma
levels of oxytocin (Hysek et al. 2014a; Hysek et al. 2014b;
Schmid et al. 2014).
The acute effects of modafinil and methylphenidate are
also different. Amphetamine and methylphenidate have
greater subjective effects than modafinil (Franke et al. 2017;
Jasinski 2000; Makris et al. 2007). In contrast, modafinil may
have greater wakefulness-promoting effects than methylphe-
nidate (Jasinski 2000; Repantis et al. 2010). In addition to
comparisons with MDMA, the present study directly com-
pared the effects of the neuroenhancers methylphenidate and
modafinil in healthy subjects, complementing a previous
study in stimulant users (Jasinski 2000).
Materials and methods
Study design
We used a double-blind, placebo-controlled, randomized,
cross-over design with four experimental sessions (125 mg
MDMA, 60 mg methylphenidate, 600 mg modafinil, and pla-
cebo) in 24 subjects. The order of the four experimental ses-
sions was counterbalanced. The washout periods between ses-
sions were at least 7 days. The study was conducted in accor-
dance with the Declaration of Helsinki and approved by the
Ethics Committee of Basel and the Swiss Agency for
Therapeutic Products (Swissmedic). All of the subjects pro-
vided written consent before participating in the study, and
they were paid for their participation. The study was registered
at ClinicalTrials.gov (NCT01951508).
Participants
Twenty-four healthy subjects (12 men, 12 women),
mean ± SD age of 22.6 ± 3.0 years (range, 19–29 years), were
recruited from the University of Basel. The inclusion criteria
were 18–45 years old and body mass index of 18–27 kg/m2.
Subjects with a personal or first-degree-relative history of psy-
chiatric disorders or chronic or acute physical illness were
excluded. Additional exclusion criteria were tobacco smoking
(>10 cigarettes/day) and a lifetime history of using illicit drugs
more than five times, with the exception of occasional canna-
bis use in the past. In contrast to similar studies in other lab-
oratories, the majority of the participants had never used
MDMA or other illicit drugs with the exception of cannabis
(Kirkpatrick et al. 2014a; Kuypers et al. 2017). Four partici-
pants had used MDMA (one–three times), two had used co-
caine on a single occasion, one had used LSD once, one psi-
locybin once, and three methylphenidate (once or twice). Four
had never used cannabis, 11 had used cannabis 1–20 times,
and 9 participants had used cannabis >20 times ranging from
once/month to 4 times per week. Subjects who used any illicit
drugs, including cannabis, within the past 2 months or during
the study period were excluded. We performed drug tests at
screening and before each test session using TRIAGE 8
(Biosite, San Diego, CA, USA). All female subjects used oral
contraceptives and were investigated during the follicular
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phase of their menstrual cycle (day 2–14 after the start of the
menstruation) to account for cyclic changes in reactivity,
which has been demonstrated for amphetamines (White
et al. 2002).
Study procedures
The study included a prescreening telephone interview, a
screening visit, four experimental sessions (test days), and
an end-of-study visit. The experimental sessions began at
8:45 AM. An indwelling intravenous catheter was placed in
an antecubital vein for blood sampling, and baseline measure-
ments were performed. MDMA, methylphenidate, modafinil,
or placebo was administered at 9:45 AM. Autonomic and
subjective effects were assessed repeatedly throughout the
session. Blood was collected to determine endocrine effects
and substance concentrations. A functional magnetic reso-
nance imaging (fMRI) scan was performed at 11:15 AM–
12:15 PM during the expected drug peak effects (Hysek
et al. 2014b; Schmid et al. 2014; Wong et al. 1998). The
fMRI findings will be published elsewhere. Face emotion rec-
ognition was assessed at 12:15 PM. A standardized small
lunch was served at 1:15 PM, and the subjects were sent home
at 3:45 PM.
Study drugs
±MDMA hydrochloride (Lipomed AG, Arlesheim,
Switzerland) was prepared as gelatin capsules with mannitol
as the filler. Identical placebo (only mannitol) capsules were
prepared. MDMAwas administered in a single absolute dose
of 125 mg corresponding to a relatively high dose of
(mean ± SD) 1.9 ± 0.3 mg/kg body weight. This dose of
MDMA is in the high range of the doses typically used in
clinical research (Kirkpatrick et al. 2015; Kirkpatrick et al.
2014a; Kuypers et al. 2017) but also used in clinical studies
in patients with PTSD (Mithoefer et al. 2010; Oehen et al.
2013) and is within the dose range that is used recreationally
(Brunt et al. 2012). Immediate-releasemethylphenidate tablets
(10 mg, Ritalin, Novartis AG, Rotkreuz, Switzerland) were
encapsulated within opaque gelatin capsules, and identical
placebo capsules were prepared. The therapeutic starting dose
of methylphenidate is 10 mg and average therapeutic doses
are 20–30 mg/day. Methylphenidate was administered in a
single relatively high dose of 60 mg (Korostenskaja et al.
2008; Martin et al. 1971). The subjective and cardiostimulant
effects of this dose have previously been assessed on the same
tests (Hysek et al. 2014b) and have also been statistically
compared with a lower dose of 40 mg (Schmid et al. 2014).
The doses of MDMA and methylphenidate used were expect-
ed to be equivalent regarding their cardiovascular stimulant
effects (Hysek et al. 2014b). Modafinil tablets (100 mg, Teva
Pharma AG, Basel, Switzerland) were encapsulated within
opaque gelatin capsules, and identical placebo capsules were
prepared. The therapeutic starting dose of modafinil is 100 mg
and common doses are 400 mg/day. Modafinil was adminis-
tered in a single high dose of 600mg. The goal was to use high
single doses of a l l substances wi th comparable
cardiostimulant effects (Hysek et al. 2014b; Jasinski 2000)
and to maximize the subjective drug effects.
Measures
Autonomic effects Blood pressure, heart rate, and tympanic
body temperature were repeatedly measured 1 h before and 0,
0.3, 0.6, 1, 1.25, 1.5, 2.5, 3, 4, 5, and 6 h after drug adminis-
tration as previously described in detail (Hysek et al. 2010).
The peak ra te-pressure product ( sys to l ic b lood
pressure × heart rate) was the main autonomic outcome mea-
sure reflecting the maximal total hemodynamic response to a
substance and expected to be comparable across substances at
the doses used (Hysek et al. 2014b; Jasinski 2000).
Subjective effects Subjective effects were assessed repeatedly
using visual analog scales (VASs) 1 h before and 0, 0.3, 0.6, 1,
1.25, 1.5, 2.5, 3, 4, 5, and 6 h after drug administration. The
VASs included Bany drug effect,^ Bgood drug effect,^ Bbad
drug effect,^ Bdrug liking,^ Bhappy,^ Bconcentration,^ Bopen,^
Btrust,^ Bfeeling close to others,^ BI want to be with other
people,^ and BI want to hug someone^ (Hysek et al. 2014a).
The VASs were presented as 100-mm horizontal lines (0–
100%), marked from Bnot at all^ on the left to Bextremely^
on the right. The 60-item Adjective Mood Rating Scale
(AMRS; (Janke and Debus 1978)) and State-Trait Anxiety
Inventory (STAI; (Spielberger et al. 1970)) were administered
1 h before and 1.25, 2.5, and 5 h after drug administration. The
German version of the 49-item Addiction Research Center
Inventory (ARCI; (Bopp et al. 2005; Martin et al. 1971))
was administered 1 h before and 1.25 h after drug administra-
tion. The 5-Dimensions of Altered States of Consciousness
(5D–ASC) scale (Dittrich 1998; Studerus et al. 2010) was
administered 5 h after drug administration to retrospectively
rate the effects of the drugs.
Endocrine effects The plasma levels of prolactin, cortisol,
oxytocin, and vasopressin were measured at baseline and 1.5
and 2.5 h after drug administration and analyzed as described
previously (Hysek et al. 2012b; Neumann et al. 2013).
Facial emotion recognition task
We used the FERT, which is sensitive to the effects ofMDMA
(Bedi et al. 2010; Hysek et al. 2014b; Kirkpatrick et al. 2014b;
Schmid et al. 2014) and methylphenidate (Hysek et al. 2014b;
Schmid et al. 2014). The task included 10 neutral faces and
160 faces that expressed one of four basic emotions (i.e.,
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happiness, sadness, anger, and fear), with pictures morphed
between 0% (neutral) and 100% in 10% steps. Two female
and twomale pictures were used for each of the four emotions.
The stimuli were presented in random order for 500 ms and
then were replaced by the rating screen where participants had
to indicate the correct emotion. The main outcome measure
was accuracy (proportion correct). Additionally, we analyzed
whether incorrectly identified emotional expressions were
misclassified as neutral or other emotions (Bedi et al. 2010;
Schmid et al. 2014). The FERTwas performed 2.5 h after drug
administration.
Sexual arousal and desire Inventory
The SADI is a self-report scale that includes 54 items (adjec-
tives or short sentences) and measures subjective sexual
arousal and desire (Persson et al. 2016; Toledano and Pfaus
2006). Each item is rated from 0 (Bdoes not describe it at all^)
to 5 (Bdescribes it perfectly^). The questionnaire includes four
overlapping factors: BEvaluative,^ BPhysiological,^
BNegative/Aversive,^ and BMotivational.^ The BEvaluative^
scale consists of 27 items that describe cognitive and emotion-
al aspects (i.e., tempted, passionate, seductive, attractive). The
BPhysiological^ scale consists of 17 items that describe auto-
nomic reactions to sexual arousal (i.e., sensitive to touch, stim-
ulated, excited, heart beats faster). The BNegative/Aversive^
scale consists of 17 items that describe aspects that are oppo-
site to sexual arousal (i.e., anxious, displeasure, repulsion,
angry). The BMotivational^ scale consists of 10 items that
are related to the motivation to engage in sexual activity
(i.e., driven, urge to satisfy, horny, impatient). The SADI
was administered 1 h before and 3 h after drug administration.
Substance plasma concentrations
The plasma levels of methylphenidate, modafinil, MDMA, and
the MDMA metabolites 3,4-methylenedioxyamphetamine
(MDA) and 4-hydroxy-3-methoxymethamphetamine
(HMMA) were determined 1 h before and 1, 1.5, 2.5, 3, 4,
and 6 h after substance administration using liquid
chromatography-mass spectrometry/mass spectrometry as pre-
viously described (Hysek et al. 2012a; Hysek et al. 2014b). The
maximal plasma concentration (Cmax) and time to Cmax (Tmax)
were obtained directly from the observed concentration-time
curves.
Adverse effects
Adverse effects were assessed 1 h before and 6 h (acute) and
24 h (sub-acute) after drug administration using the 66-item
List of Complaints (Zerssen 1976). The scale yields a total
adverse effects score and reliably measures physical and gen-
eral discomfort.
Statistical analyses
Repeated measures are expressed as peak effects or peak
changes from baseline (Emax). The data were analyzed using
repeated-measures analysis of variance (ANOVA), with drug
as the within-subjects factor, followed by Tukey post hoc
comparisons based on significant main effects. Some of the
VASs data were not normally distributed and were therefore
analyzed using Friedman ANOVAs with drug as the within-
subject factor, followed byWilcoxon matched pairs tests. The
criterion for significance was p < 0.05. The criterion was ad-
justed for the multiple comparisons within the VAS and the
AMRS using the Bonferroni method.
Results
All 24 participants completed all sessions of the study.
Autonomic, subjective, and endocrine peak effects and statis-
tics are shown in Table 1 and Supplementary Table S1.
Autonomic effects
Drug effects on vital signs over time are shown in Fig. 1, and
peak effects are shown in Table 1. All active substances pro-
duced comparable and significant increases in body tempera-
ture and similar hemodynamic stimulation, considering the sim-
ilar increase in the rate-pressure products compared with place-
bo. MDMA markedly and significantly increased pupil size in
the dark and after a light stimulus and decreased the constriction
amplitude. Methylphenidate and modafinil produced only very
small but significant increases in pupil size in the dark. MDMA
produced significantly greater alterations in pupil function than
methylphenidate and modafinil, including markedly greater pu-
pil size in the dark and significantly lower responses to a light
stimulus (Supplementary Fig. S1, Table 1).
Subjective effects
Subjective drug effects over time are shown in Fig. 2 and Fig. 3,
and peak responses are shown in Table 1 and Supplementary
Table S1. On the VASs (Fig. 2), MDMA increased ratings for
any drug effect, good drug effect, drug liking, happiness, open,
trust, feeling close to others, I want to be with other people, and I
want to hug someone compared with placebo. Methylphenidate
produced significant increases in any drug effect, good drug
effect, and drug liking but only very small increases in ratings
of open, and feeling close to others compared with placebo.
Modafinil produced no significant subjective effects compared
with placebo. MDMA increased ratings for any drug effect,
good drug effect, drug liking, happy, trust, feeling close to
others, and want to be with other people more than methylphe-
nidate or modafinil. On the AMRS (Fig. 3), MDMA increased
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Table 1 Comparison of the acute effects of MDMA, methylphenidate, modafinil, and placebo (N = 24)
Placebo MDMA Methylphenidate Modafinil
(mean ± SEM) (mean ± SEM) (mean ± SEM) (mean ± SEM) F 3.69 p=
Autonomic effects
Systolic blood pressure (mm Hg) Emax 135 ± 3.0 152 ± 3.2*** 145 ± 3.1***# 143 ± 3.4**## 20.41 <0.001
Diastolic blood pressure (mm Hg) Emax 78.8 ± 1.6 88.1 ± 1.8*** 84.0 ± 1.8**# 85.7 ± 2.0*** 13.24 <0.001
Heart rate (beats/min) Emax 73.1 ± 2.5 90.3 ± 3.0*** 91.6 ± 3.6*** 87.9 ± 3.5*** 23.82 <0.001
Rate pressure product (beats·mmHg/min) Emax 9603 ± 383 13,377 ± 536*** 12,985 ± 625*** 12,273 ± 667*** 26.15 <0.001
Body temperature (°C) Emax 37.3 ± 0.1 37.6 ± 0.1** 37.6 ± 0.1** 37.9 ± 0.1*** 12.55 <0.001
Pupil size (mm) Emax 6.5 ± 0.1 7.4 ± 0.1*** 6.7 ± 0.1**### 6.7 ± 0.2*### 76.11 <0.001
Pupil size after light stimulus (mm) Emax 4.7 ± 0.1 6.4 ± 0.2*** 4.8 ± 0.1### 4.8 ± 0.1### 148.78 <0.001
Constriction amplitude (mm) Emin 1.8 ± 0.1 0.86 ± 0.10*** 1.8 ± 0.1### 1.7 ± 0.1### 34.47 <0.001
Subjective effects
Visual Analog Scale (VAS, %max)
Any drug effect ΔEmax 10.0 ± 2.4 75.3 ± 5.1*** 32.8 ± 6.8*### 23.7 ± 5.2### 45.51 <0.001
Good drug effect ΔEmax 7.5 ± 2.5 73.2 ± 5.3*** 35.5 ± 7.7**### 23.9 ± 5.4### 45.68 <0.001
Bad drug effect ΔEmax 4.2 ± 3.3 12.7 ± 3.5 11.5 ± 4.5 10.3 ± 4.9 10.49 NS
Drug liking ΔEmax 9.4 ± 3.0 75.5 ± 5.5*** 36.3 ± 8.2*### 24.8 ± 5.4### 40.9 <0.001
Happy ΔEmax 2.7 ± 1.2 31.0 ± 3.6*** 10.8 ± 3.6## 8.1 ± 2.4### 41.06 <0.001
Concentration ΔEmax −6.5 ± 1.5 −29.3 ± 3.4 −11.6 ± 3.6 −13.3 ± 3.6 9.56 NS
Open ΔEmax 2.4 ± 1.0 19.6 ± 3.7** 11.2 ± 3.5* 9.5 ± 2.9 20.08 <0.01
Trust ΔEmax 1.5 ± 0.9 24.5 ± 4.1** 8.0 ± 3.0## 8.6 ± 3.7# 24.85 <0.001
Feeling close to others ΔEmax 1.1 ± 0.8 18.5 ± 3.8** 9.7 ± 2.6*# 5.7 ± 2.1# 24.79 <0.001
I want to be with other people ΔEmax 3.1 ± 1.9 21.0 ± 4.3*** 10.1 ± 3.5# 9.9 ± 3.8# 18.46 <0.01
I want to hug someone ΔEmax 0.6 ± 0.6 15.1 ± 3.6* 7.0 ± 3.3 3.3 ± 2.3# 23.13 <0.001
Adjective Mood Rating Scale (AMRS score)
Well-being ΔEmax 0.04 ± 0.37 5.8 ± 1.0*** 2.5 ± 0.7# 1.3 ± 0.7## 14.52 <0.001
Emotional excitation ΔEmax −0.13 ± 0.56 3.0 ± 0.9* 2.6 ± 0.8 1.2 ± 0.7 4.91 <0.05
Activity ΔEmax 0.79 ± 0.45 2.0 ± 0.6 2.5 ± 0.5 0.50 ± 0.4 3.23 NS
Extroversion ΔEmax 0.0 ± 0.4 2.3 ± 0.6** 1.3 ± 0.5 1.36 ± 0.5 5.25 <0.05
Introversion ΔEmax 0.50 ± 0.29 2.4 ± 0.5* 1.3 ± 0.4 0.9 ± 0.4 4.36 <0.05
Concentration ΔEmax 0.3 ± 0.32 0.46 ± 0.46 1.13 ± 0.42 −0.33 ± 0.25 3.05 NS
State-Trait Anxiety Inventory (state anxiety score)
Emax 36.6 ± 1.0 37.6 ± 1.4 42.0 ± 1.8* 39.5 ± 1.6 3.25 <0.05
Emin 32.8 ± 0.9 29.0 ± 1*** 34.5 ± 1.0### 32.5 ± 1.2# 6.58 <0.001
Sexual Arousal and Desire Inventory
Evaluative 1.4 ± 1.3 19.5 ± 4.3*** 6.5 ± 3.4# 8.4 ± 3.6# 6.98 <0.001
Negative/Aversive 0.04 ± 1.3 −0.09 ± 1.5 0.3 ± 1.4 4.9 ± 2.6 1.88 NS
Physiological 1.6 ± 0.9 13.2 ± 2.4*** 6.6 ± 2.4# 5.0 ± 2.2## 8.03 <0.001
Motivational 0.4 ± 0.6 4.8 ± 1.5* 1.1 ± 1.2 2.5 ± 1.4 3.22 <0.05
Hormones
Cortisol (nmol/L) Emax 630 ± 53.5 942 ± 41.5*** 648 ± 37.7**### 653 ± 40.5### 35.55 <0.001
Prolactin (mU/L) Emax 334 ± 32.7 1086 ± 143*** 295 ± 30.9### 288 ± 24.0### 30.46 <0.001
Oxytocin (pg/mL) Emax 5.0 ± 1.5 58.7 ± 7.9*** 6.3 ± 1.3### 4.29 ± 0.87### 44.90 <0.001
Vasopressin (pg/mL) Emax 4.1 ± 0.3 4.4 ± 0.5 4.23 ± 0.67 3.44 ± 0.27 2.15 NS
VAS and AMRS P values were Bonferroni adjusted values considering the multiple subscales used (11 and 6 for the VAS and AMRS, respectively)
NS not significant, Emax maximal effect, ΔEmax maximal difference from baseline
*p < 0.05, **p < 0.01, ***p < 0.001 compared with placebo; #p < 0.05, ##p < 0.01, ###p < 0.001 compared with MDMA
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Fig. 1 Autonomic responses to MDMA, methylphenidate, modafinil,
and placebo. All active treatments increased systolic and diastolic blood
pressure, heart rate, and body temperature. MDMA produced slightly
higher increases in blood pressure than methylphenidate and modafinil.
However, the overall hemodynamic response, expressed as the rate
pressure product, similarly increased after all active treatments
compared with placebo. The data are expressed as the mean ± SEM in
24 subjects. The substances were administered at t = 0
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well-being, emotional excitation, extraversion, and introversion
compared with placebo. Methylphenidate and modafinil had no
effects on the AMRS. MDMA increased well-being more than
methylphenidate or modafinil. On the STAI (Fig. 3), MDMA
reduced state anxiety, methylphenidate increased anxiety, and
modafinil had no effect. On the ARCI (Supplementary
Table S1), MDMA increased amphetamine-group, morphine,
and pentobarbital-chlorpromazine-alcohol group ratings com-
pared with placebo. Methylphenidate increased amphetamine
and benzedrine group ratings compared with placebo.
Modafinil had no significant effects on the ARCI. MDMA in-
creased morphine and pentobarbital-chlorpromazine-alcohol
group ratings significantly more than methylphenidate and
modafinil. On the 5D-ASC scale (Supplementary Table S1),
MDMAproduced effects on oceanic boundlessness and anxious
ego dissolution. Methylphenidate and modafinil had no effects
on any of the 5D-ASC scales.
Endocrine effects
MDMA increased plasma concentrations of cortisol, prolac-
tin, and oxytocin compared with placebo and all of the other
active treatments (Fig. 4, Table 1). Methylphenidate produced
a slight increase in cortisol concentrations, and modafinil had
no effect. None of the active treatments increased vasopressin
concentrations.
Facial emotion recognition
The effects of MDMA, methylphenidate, and modafinil
on the FERT are shown in Fig. 5. Complete datasets were
unavailable for two subjects because of technical reasons.
The ANOVA revealed a significant main effect of drug on
the decoding accuracy of fearful faces (F3,63 = 7.38
p < 0.001). The post hoc tests showed that MDMA sig-
nificantly impaired the recognition of fearful faces com-
pared with placebo (p < 0.001), methylphenidate
(p < 0.01), and modafinil (p < 0.05). There was a signif-
icant main effect of drug on misclassification of emotions
as happy (F3,63 = 3.35 p < 0.05). MDMA significantly
increased the misclassification of emotions as happy com-
pared with placebo (p < 0.05). In contrast, methylpheni-
date (p < 0.05) and modafinil (p < 0.05) increased mis-
classifications of emotions as angry (main effect of drug:
F3,63 = 3.38 p < 0.05). However, methylphenidate and
modafinil did not alter emotion recognition accuracy for
any of the emotions.
Sexual arousal and desire
Data from one subject were missing. Only MDMA increased
scores on the BEvaluative^ (p < 0.001), BPhysiological^
(p < 0.001), and BMotivational^ (p < 0.05) scales compared
with placebo, but it did not influence scores on the BNegative/
Aversive^ scale (Table 1). MDMA produced significantly
higher ratings on the BPhysiological^ factor items Btingly all
over,^ Bsensitive to touch,^ Benthusiastic,^ Bwarm all over,^
Bflushed,^ Bheart beats faster,^ and Bseductive^ compared
with placebo. MDMA produced significantly higher ratings
on the BEvaluative^ factor items Benthusiastic,^ Bwarm all
over,^ Bpassionate,^ Bsensual,^ Bpleasure,^ Bheart beats
faster,^ Bhappy,^ Bpowerful,^ and Bforget about all else^
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Fig. 3 On the AMRS, MDMA significantly increased ratings of well-
being, emotional excitation, extroversion, and introversion.
Methylphenidate and modafinil produced no effects on any of the
AMRS scales. On the STAI, MDMA decreased state anxiety, and
methylphenidate increased state anxiety. The data are expressed as the
mean ± SEM in 24 subjects. The substances were administered at t = 0
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compared with placeboMDMA produced significantly higher
ratings on the BMotivational^ factor item Banticipatory^ com-
pared with placebo.
Substance plasma concentrations
The concentration-time curves for methylphenidate,
modafinil, MDMA, MDA, and HMMA are shown in
Supplementary Fig. S2. The Cmax values for MDMA, MDA,
and HMMAwere 192 ± 8.7, 9.1 ± 0.4, and 69.1 ± 10.0 ng/ml,
respectively. The Tmax values were 3.7 ± 0.3, 5.7 ± 0.2, and
4.2 ± 0.3 h, respectively. The Cmax values for methylphenidate
and modafinil were 27.0 ± 2.1 and 13.2 ± 0.5 μg/ml,
respectively. The Tmax values were 3.2 ± 0.3 and 3.3 ± 0.3 h,
respectively.
Adverse effects
On the List of Complaints, MDMA, methylphenidate, and
modafinil produced significant and comparable acute adverse
effects (up to 6 h) compared with placebo (Supplementary
Table S1). The most frequent acute complaints were lack of
appetite, dry mouth, and headache. Only modafinil produced
significant adverse effects that lasted up to 24 h (mostly in-
somnia, headache, and lack or appetite). There were no severe
adverse effects.
Discussion
The main finding of the present study was that oral administra-
tion of MDMA produced acute subjective, emotional, sensual/
sexual, and endocrine effects that were clearly distinct from
those of the stimulant drugs methylphenidate and modafinil at
oral doses that produced comparable sympathomimetic stimu-
lant effects. The acute effects of MDMA (Dumont et al. 2009;
Farre et al. 2004; Hysek et al. 2011; Kirkpatrick et al. 2014b;
Liechti et al. 2001; Vollenweider et al. 1998), methylphenidate
(Hysek et al. 2014b; Schmid et al. 2015b; Schmid et al. 2014),
and modafinil (Jasinski 2000; Rush et al. 2002; Turner et al.
2003; Wong et al. 1999) have been previously described in
healthy subjects. The present study further compared their
acute responses within the same study and within the same
Time (min)
C
o
r
ti
s
o
l 
(
n
M
o
l/
l)
0
200
400
600
800
1000
0 90 150
Time (min)
Time (min) Time (min)
P
r
o
la
c
ti
n
 (
m
U
/l
)
0
200
400
600
800
1000
1200
0 90 150
O
x
y
to
c
in
 (
p
g
/m
L
)
20
40
60
0 90 150
90 150
0
V
a
s
o
p
r
e
s
s
in
 (
p
g
/m
L
)
0
2
4
6
0
Methylphenidate PlaceboMDMA Modafinil
Fig. 4 Endocrine effects of
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increase in cortisol comparedwith
placebo. Modafinil had no
endocrine effects. The data are
expressed as the mean ± SEM in
24 subjects. The substances were
administered at t = 0
F
a
c
ia
l 
e
m
o
ti
o
n
 r
e
c
o
g
n
it
io
n
 t
a
s
k
(
%
c
o
r
r
e
c
t)
Neutral Happy Sad Anger Fear
30
40
50
60
70
80
Placebo
MDMA
Methylphenidate
Modafinil
*
*
*
Fig. 5 On the Facial Emotion Recognition Task, MDMA significantly
impaired the recognition of fearful faces compared with placebo.
Methylphenidate and modafinil did not significantly alter emotion
recognition. The data are expressed as the mean ± SEM in 22 subjects
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subjects, thus providing direct and valid comparisons. The use
of four drug conditions in the within-subject study eliminated
any between-subject or between-study differences in compari-
sons of drug characteristics, and all drugs were administered
blind in both active and passive control conditions. The prima-
ry research question was whetherMDMA is simply a stimulant
or whether it has unique namely prosocial and empathogenic
effects that are distinct from other stimulants (Bershad et al.
2016). The present study clearly indicated that MDMA has a
different effect profile than the stimulant methylphenidate at the
doses used, supporting previous, albeit less rigorous, study
findings (Bershad et al. 2016; Hysek et al. 2014b; Schmid
et al. 2015b; Schmid et al. 2014). Specifically, MDMA in-
creased well-being, good drug effects, drug liking, happiness,
trust, feelings of closeness to others, and wanting to be with
others, and reduced state anxiety compared with methylpheni-
date and modafinil at the doses used. The distinct mood effects
of MDMAwere congruent with its effects on the FERT, includ-
ing reductions of fear recognition and more misclassifications
of emotions as happy. MDMA, but not methylphenidate, has
previously been shown to reduce fear recognition on the FERT
(Bedi et al. 2010; Hysek et al. 2014b; Kirkpatrick et al. 2014b;
Schmid et al. 2014). Additionally, MDMA, but not methylphe-
nidate or modafinil, strongly increased endocrine markers of
acutely increased serotonergic activity, including cortisol and
prolactin (Seifritz et al. 1996; Sommers et al. 1994; Strajhar
et al. 2016). MDMA, but not methylphenidate or modafinil,
also markedly increased pupil size at rest and after light stimu-
lation, which is consistent with a previous study (Hysek and
Liechti 2012) and other serotonergic substances (Schmid et al.
2015a). On the ARCI, methylphenidate and modafinil pro-
duced significantly fewer sedating effects than MDMA, which
is consistent with their greater stimulant-type properties.
Pharmacologically, MDMA (Hysek et al. 2012c; White
et al. 1996), methylphenidate (Han and Gu 2006; Rothman
et al. 2001; Schmeichel and Berridge 2013), and modafinil
(Madras et al. 2006; Rowley et al. 2014) all stimulate the
noradrenergic system and consistently produced overall simi-
lar cardiostimulant effects in the present study. Additionally,
MDMA releases serotonin (Hysek et al. 2012c; White et al.
1996) and oxytocin (Dumont et al. 2009; Hysek et al. 2012b;
Hysek et al. 2014a; Kuypers et al. 2017; Schmid et al. 2014;
Thompson et al. 2007), whereas methylphenidate and
modafinil act as dopamine uptake inhibitors (Madras et al.
2006; Rothman et al. 2001). Consistent with the different
pharmacological profiles of these substances, MDMA exerted
distinct subjective effects across all of our rating scales (VASs,
AMRS, ARCI, 5D-ASC, and SADI) compared with methyl-
phenidate and modafinil at the doses used. Consistent with the
present study, we previously reported greater well-being, hap-
piness, extroversion, and feelings of closeness after 125 mg
MDMA administration compared with 60 mg methylpheni-
date (Hysek et al. 2014b) and after 75 mg MDMA
administration compared with 40 mg methylphenidate
(Schmid et al. 2014).
In the present study, MDMA increased circulating concen-
trations of cortisol, prolactin, and oxytocin as previously shown
for different doses of MDMA (Harris et al. 2002; Hysek et al.
2012b; Hysek et al. 2014a; Joyce et al. 1986; Kirkpatrick et al.
2014b;Mas et al. 1999; Schmid et al. 2014; Seibert et al. 2014).
MDMA did not alter plasma concentrations of vasopressin,
which is consistent with previous studies that reported no
change in the concentrations of the vasopressin precursor
copeptin (Hysek et al. 2014a; Schmid et al. 2014). In contrast,
higher levels of vasopressin following MDMA administration
were reported in some earlier studies (Forsling et al. 2001;
Henry et al. 1998), and one study reported higher concentra-
tions of the vasopressin precursor copeptin in females (Simmler
et al. 2011). Methylphenidate only slightly increased plasma
concentrations of cortisol in the present study, which is consis-
tent with no or weak effects of methylphenidate that were re-
ported in other studies (Hysek et al. 2014b; Joyce et al. 1986;
Schmid et al. 2014; Seibert et al. 2014). Modafinil had no
effects on plasma cortisol, prolactin, oxytocin, or vasopressin
concentrations, which is consistent with previous reports for
cortisol (Brun et al. 1998). Altogether, the main endocrine find-
ing of the present study was that only MDMA produced
marked increases in cortisol, prolactin, and oxytocin concentra-
tions, which is consistent with similar effects of other seroto-
nergic substances (Schmid et al. 2015a; Seibert et al. 2014;
Seifritz et al. 1996; Strajhar et al. 2016).
The present study used a relatively high dose of modafinil
(600 mg), which did not produce significant or relevant subjec-
tive effects despite pronounced cardiostimulant and adverse ef-
fects, including insomnia, that lasted up to 24 h. Similarly,
modafinil produced no subjective mood effects at doses of
100–400 mg (Franke et al. 2017; Muller et al. 2013; Scoriels
et al. 2011; Turner et al. 2003). However, modafinil increased
misclassifications of emotions as angry on the FERT. Higher
subjective anxiety and aggression were reported after administra-
tion of 100 and 200 mgmodafinil in young (Randall et al. 2003)
but not middle-aged (Randall et al. 2004) healthy volunteers.
Modafinil improved the recognition of sad faces in psychotic
patients (Scoriels et al. 2011), a finding that was not replicated
in the present study in healthy subjects. Consistent with its use as
a promoter of wakefulness, 100 and 200 mgmodafinil increased
alertness in healthy subjects in another study (Turner et al. 2003).
Compared with the present study that used a relatively high dose
of 600 mg, modafinil had moderate hemodynamic effects at
doses of 100–200 mg (Turner et al. 2004; Turner et al. 2003).
In contrast to modafinil, methylphenidate produced signif-
icant subjective good drug effects and drug liking and pro-
duced moderate increases in feeling open and close to others
compared with placebo. In contrast to the effects of MDMA,
methylphenidate increased STAI state anxiety and tended to
increase subjective concentration, which is consistent with its
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stimulant properties and use as a cognitive enhancer (Liakoni
et al. 2015; Maier et al. 2015; Maier et al. 2013).
In the present study and at the doses used, MDMA, but not
methylphenidate or modafinil, increased ratings of sexual
arousal and desire on the SADI. This finding was unexpected
because dopaminergic stimulants, including cocaine, metham-
phetamine, andmethylphenidate, have been previously shown
to increase sexual desire and arousal (Frohmader et al. 2010;
Rawson et al. 2002; Schmid et al. 2015b; Semple et al. 2002).
Interestingly, intravenous (Volkow et al. 2007) but not oral
(Volkow et al. 2007) administration of methylphenidate en-
hanced self-reported sexual desire, which is consistent with
the lack of sexual stimulant effects of oral methylphenidate
that was observed in the present study.We previously reported
that methylphenidate, but not MDMA, increased sexual
arousal that was elicited by explicit visual sexual stimuli
(Schmid et al. 2015b). The SADI is very different from the
test that was used in the previous study. No stimuli were pre-
sented, and subjects simply rated the intensity of various sen-
sations that are typically related to sexual stimulation but with-
out a specific sexual context or related stimuli. MDMA in-
creased many sensations that comprise the BEvaluative^ and
BPhysiological^ factors of the SADI, including ratings of en-
thusiastic, happy, sensual, pleasure, warm all over, and heart
beats faster, in a potentially nonspecific sexually related man-
ner. Although the subjects were instructed to make ratings on
the SADI specifically with regard to sexual arousal and desire,
their ratings may have been confounded by direct somatic and
subjective drug effects of MDMA that are unrelated to sexual
stimulation. Thus, one may argue that MDMA produced
many physiological effects that also coincide with sexual
arousal. Other studies reported increases in sexual arousal af-
ter methylphenidate but not MDMA administration
(Frohmader et al. 2010; Schmid et al. 2015b; Volkow et al.
2007). MDMA users report inconsistent effects on sexual
arousal and desire (McElrath 2005; Passie et al. 2005; Theall
et al. 2006). MDMA appears to enhance pleasurable sensa-
tions, touch, and physical closeness rather than actual sexual
engagement, and it reportedly impairs sexual performance
(Frohmader et al. 2010; Passie et al. 2005; Theall et al.
2006; Zemishlany et al. 2001). Remaining unclear is whether
MDMA produces actual sexual arousal or heightened motiva-
tion to engage in sexual activity.
The present study has limitations.Wemainly used only one
dose of each substance. It is difficult if not impossible to
compare active substances if only one dose is used. Thus,
the observed differences between drugs were seen at the doses
used in this study but may not be present at different doses.
However, dose-effect relationships show Emax curve charac-
teristics (Hysek et al. 2012c) and we used single but relatively
high doses of all drugs expected to result in subjective drug
effects close to Emax based on previous studies (Hysek et al.
2012a; Hysek et al. 2012c). MDMAwas used at an average
dose of 1.9 mg/kg resulting in high mean peak plasma con-
centrations of 192 ng/ml clearly above the EC50 values of 44
and 93 ng/ml MDMA for the cardiostimulant and subjective
effects, respectively (Hysek et al. 2012a; Hysek et al. 2012c).
Thus, it can be assumed that near-maximal effects were
reached at the MDMA dose used in the present study.
Similarly, the single doses of methylphenidate and modafinil
were high (sixfold the therapeutic starting doses for both sub-
stances), and plasma concentrations of methylphenidate and
modafinil were twofold higher compared to those in another
study using lower doses (Franke et al. 2017). Importantly, all
of the drugs produced comparable overall sympathomimetic
stimulation as reflected by the similar increase in the peak
rate-pressure product and consistent with our attempt to match
the doses based on previous data (Hysek et al. 2014b; Jasinski
2000) to produce similar cardiovascular effects. The distinct
effects of MDMA and the other two stimulants were seen at
the doses used in the present study. However, similarly distinct
profiles were reported for MDMA and methylphenidate using
identical and also lower doses of both substances and includ-
ing also dose-response analyses (Hysek et al. 2014b; Schmid
et al. 2014). The plasma concentration-time curves of all sub-
stances and metabolites measured in the present study were in
the expected range based on pharmacokinetic data from other
studies (de la Torre et al. 2000; Wong et al. 1998). The Cmax
was similar, but the mean Tmax (3.2 h) of methylphenidate was
longer compared with our previous study (2.3 h) (Hysek et al.
2014b). Importantly, Tmax values were comparable for all sub-
stances used in the present study. Nevertheless, it should be
acknowledged that comparisons across substances could be
biased by differences in dose and pharmacokinetics.
Another issue relates to the use of many psychometric
scales in the present study with the intention to more compre-
hensively and sensitively describe and compare the effects of
the psychoactive substances. This may have increased the risk
of change findings. However, the primary study hypothesis of
greater socioemotional effects of MDMA compared to meth-
ylphenidate and modafinil at the doses used was confirmed.
However, the differential effects of the substances on the
STAI, ARCI, and SADI should be regarded as exploratory.
In conclusion, MDMA produced acute subjective, emo-
tional, and endocrine effects that were distinct from those of
methylphenidate and modafinil at the doses used, which is
consistent with their different pharmacological profiles.
Modafinil produced acute sympathomimetic stimulation that
was comparable to methylphenidate and MDMA, but
modafinil produced no emotional or subjective effects at the
relatively high dose used.
Acknowledgements The authors acknowledge the assistance of
Samuel Harder and Niklaus Denier in study management, Urs Duthaler
and Anna Rickli in the measurement of drug plasma concentrations, and
Michael Arends for text editing.
476 Psychopharmacology (2018) 235:467–479
Francis SM, Kirkpatrick MG, de Wit H, Jacob S (2016) Urinary and
plasma oxytocin changes in response to MDMA or intranasal oxy-
tocin administration. Psychoneuroendocrinology 74:92–100
Franke AG, Gransmark P, Agricola A, Schuhle K, Rommel T, Sebastian
A, Ballo HE, Gorbulev S, Gerdes C, Frank B, Ruckes C, Tuscher O,
Lieb K (2017) Methylphenidate, modafinil, and caffeine for cogni-
tive enhancement in chess: a double-blind, randomised controlled
trial. Eur Neuropsychopharmacol 27:248–260
Frohmader KS, Pitchers KK, Balfour ME, Coolen LM (2010) Mixing
pleasures: review of the effects of drugs on sex behavior in humans
and animal models. Horm Behav 58:149–162
Han DD, Gu HH (2006) Comparison of the monoamine transporters from
human and mouse in their sensitivities to psychostimulant drugs.
BMC Pharmacol 6:6
Hannestad J, Gallezot JD, Planeta-Wilson B, Lin SF, Williams WA, van
Dyck CH, Malison RT, Carson RE, Ding YS (2010) Clinically rel-
evant doses of methylphenidate significantly occupy norepinephrine
transporters in humans in vivo. Biol Psychiatry 68:854–860
Harris DS, Baggott M, Mendelson JH, Mendelson JE, Jones RT (2002)
S u b j e c t i v e a n d h o r m o n a l e f f e c t s o f 3 , 4 -
methylenedioxymethamphetamine (MDMA) in humans.
Psychopharmacology 162:396–405
Henry JA, Fallon JK, Kicman AT, Hutt AJ, Cowan DA, Forsling M
(1998) Low-dose MDMA (Becstasy^) induces vasopressin secre-
tion. Lancet 351:1784
Hysek CM, Liechti ME (2012) Effects of MDMA alone and after
pretreatement with reboxetine, duloxetine, clonidine, carvedilol,
and doxazosin on pupillary light reflex. Psychopharmacology 224:
363–376
Hysek CM, Vollenweider FX, Liechti ME (2010) Effects of a beta-
blocker on the cardiovascular response to MDMA (ecstasy).
Emerg Med J 27:586–589
Hysek CM, Simmler LD, Ineichen M, Grouzmann E, Hoener MC,
Brenneisen R, Huwyler J, Liechti ME (2011) The norepinephrine
transporter inhibitor reboxetine reduces stimulant effects of MDMA
(Becstasy^) in humans. Clin Pharmacol Ther 90:246–255
Hysek CM, Brugger R, Simmler LD, Bruggisser M, Donzelli M,
Grouzmann E, Hoener MC, Liechti ME (2012a) Effects of the al-
pha2-adrenergic agonist clonidine on the pharmacodynamics and
pharmacokinetics of 3,4-methylenedioxymethamphetamine in
healthy volunteers. J Pharmacol Exp Ther 340:286–294
Hysek CM, Domes G, Liechti ME (2012b) MDMA enhances Bmind
reading^ of positive emotions and impairs Bmind reading^ of nega-
tive emotions. Psychopharmacology 222:293–302
Hysek CM, Simmler LD, Nicola V, Vischer N, Donzelli M, Krähenbühl
S, Grouzmann E, Hoener MC, Liechti ME (2012c) Duloxetine in-
hibits effects of MDMA (Becstasy^) in vitro and in humans in a
randomized placebo-controlled laboratory study. PLoS One 7:
e36476
Hysek CM, Schmid Y, Simmler LD, Domes G, Heinrichs M, Eisenegger
C, Preller KH, QuednowBB, Liechti ME (2014a)MDMA enhances
emotional empathy and prosocial behavior. Soc Cogn Affect
Neurosci 9:1645–1652
Hysek CM, Simmler LD, Schillinger N,Meyer N, Schmid Y, Donzelli M,
Grouzmann E, Liechti ME (2014b) Pharmacokinetic and pharma-
codynamic effects of methylphenidate and MDMA administered
alone and in combination. Int J Neuropsychopharmacol 17:371–381
Janke W, Debus G (1978) Die Eigenschaftswörterliste. Hogrefe,
Göttingen
Jasinski DR (2000) An evaluation of the abuse potential of modafinil
using methylphenidate as a reference. J Psychopharmacol 14:53–60
Joyce PR, Donald RA, Nicholls MG, Livesey JH, Abbott RM (1986)
Endocrine and behavioral responses to methylphenidate in normal
subjects. Biol Psychiatry 21:1015–1023
Kamilar-Britt P, Bedi G (2015) The prosocial effects of 3,4-
methylenedioxymethamphetamine (MDMA): controlled studies in
Psychopharmacology (2018) 235:467–479 477
Compliance with ethical standards The study was conducted in ac-
cordance with the Declaration of Helsinki and approved by the local
ethics committee. All of the subjects provided written consent before
participating in the study.
Conflict of interest The authors declare that they have no conflict of
interest.
Funding This work was supported by the Swiss National Science
Foundation (grant no. 320030_170249 to MEL and SB) and the
University of Basel (to FM).
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a link
to the Creative Commons license, and indicate if changes were made.
References
Bedi G, Hyman D, deWit H (2010) Is ecstasy an Bempathogen^? Effects
of ±3,4-methylenedioxymethamphetamine on prosocial feelings
and identification of emotional states in others. Biol Psychiatry 68:
1134–1140
Bershad AK, Miller MA, Baggott MJ, de Wit H (2016) The effects of
MDMA on socio-emotional processing: does MDMA differ from
other stimulants? J Psychopharmacol 30:1248–1258
Bopp G, Bender W, Schütz CG (2005) Validierung der Deutschen
Version des Addiction Research Center Inventory (ARCI).
Suchtmedizin 7:152–153
Brun J, Chamba G, Khalfallah Y, Girard P, Boissy I, Bastuji H, Sassolas
G, Claustrat B (1998) Effect of modafinil on plasma melatonin,
cortisol and growth hormone rhythms, rectal temperature and per-
formance in healthy subjects during a 36 h sleep deprivation. J Sleep
Res 7:105–114
Brunt TM, Koeter MW, Niesink RJ, van den BrinkW (2012) Linking the
pharmacological content of ecstasy tablets to the subjective experi-
ences of drug users. Psychopharmacology 220:751–762
de la Torre R, Farre M, Roset PN, Lopez CH, Mas M, Ortuno J, Menoyo
E, Pizarro N, Segura J, Cami J (2000) Pharmacology of MDMA in
humans. Ann N YAcad Sci 914:225–237
Dittrich A (1998) The standardized psychometric assessment of altered
states of consciousness (ASCs) in humans. Pharmacopsychiatry
31(Suppl 2):80–84
Dumont GJ, Verkes RJ (2006) A review of acute effects of 3,4-
methylenedioxymethamphetamine in healthy volunteers. J
Psychopharmacol 20:176–187
Dumont GJ, Sweep FC, van der Steen R, Hermsen R, Donders AR, Touw
DJ, van Gerven JM, Buitelaar JK, Verkes RJ (2009) Increased oxy-
tocin concentrations and prosocial feelings in humans after ecstasy
(3,4-methylenedioxymethamphetamine) administration. Soc
Neurosci 4:359–366
Farre M, de la Torre R, Mathuna BO, Roset PN, Peiro AM, Torrens M,
Ortuno J, Pujadas M, Cami J (2004) Repeated doses administration
of MDMA in humans: pharmacological effects and pharmacokinet-
ics. Psychopharmacology 173:364–375
Forsling M, Fallon JK, Kicman AT, Hutt AJ, Cowan DA, Henry JA
(2001) Arginine vasopressin release in response to the administra-
tion of 3,4-methylenedioxymethamphetamine (Becstasy^): is metab-
olism a contributory factor? J Pharm Pharmacol 53:1357–1363
humans and laboratory animals. Neurosci Biobehav Rev 57:433–
446
Kirkpatrick MG, Baggott MJ, Mendelson JE, Galloway GP, Liechti ME,
Hysek CM, de Wit H (2014a) MDMA effects consistent across
laboratories. Psychopharmacology 231:3899–3905
Kirkpatrick MG, Lee R, Wardle MC, Jacob S, de Wit H (2014b) Effects
of MDMA and intranasal oxytocin on social and emotional process-
ing. Neuropsychopharmacology 39:1654–1663
Kirkpatrick M, Delton AW, Robertson TE, de Wit H (2015) Prosocial
effects of MDMA: a measure of generosity. J Psychopharmacol 29:
661–668
Korostenskaja M, Kicic D, Kahkonen S (2008) The effect of methylphe-
nidate on auditory information processing in healthy volunteers: a
combined EEG/MEG study. Psychopharmacology 197:475–486
Kuypers KPC, Dolder PC, Ramaekers JG, Liechti ME (2017)
Multifaceted empathy of healthy volunteers after single doses of
MDMA: a pooled sample of placebo-controlled studies. J
Psychopharmacol 31:589–598
Liakoni E, SchaubMP,Maier LJ, Glauser GV, LiechtiME (2015) The use
of prescription drugs, recreational drugs, and Bsoft enhancers^ for
cognitive enhancement among Swiss secondary school students.
PLoS One 10:e0141289
Liechti M (2015) Novel psychoactive substances (designer drugs): over-
view and pharmacology of modulators of monoamine signaling.
Swiss Med Wkly 145:w14043
Liechti ME, Gamma A, Vollenweider FX (2001) Gender differences in
the subjective effects of MDMA. Psychopharmacology 154:161–
168
Madras BK, Xie Z, Lin Z, Jassen A, Panas H, Lynch L, Johnson R, Livni
E, Spencer TJ, Bonab AA, Miller GM, Fischman AJ (2006)
Modafinil occupies dopamine and norepinephrine transporters
in vivo and modulates the transporters and trace amine activity
in vitro. J Pharmacol Exp Ther 319:561–569
Maier LJ, Liechti ME, Herzig F, Schaub MP (2013) To dope or not to
dope: neuroenhancement with prescription drugs and drugs of abuse
among Swiss university students. PLoS One 8:e77967
Maier LJ, Liakoni E, Schildmann J, SchaubMP, Liechti ME (2015) Swiss
university students’ attitudes toward pharmacological cognitive en-
hancement. PLoS One 10:e0144402
Makris AP, Rush CR, Frederich RC, Taylor AC, Kelly TH (2007)
Behavioral and subjective effects of d-amphetamine and modafinil
in healthy adults. Exp Clin Psychopharmacol 15:123–133
Martin WR, Sloan JW, Sapira JD, Jasinski DR (1971) Physiologic, sub-
jective, and behavioral effects of amphetamine, methamphetamine,
ephedrine, phenmetrazine, and methylphenidate in man. Clin
Pharmacol Ther 12:245–258
Mas M, Farre M, de la Torre R, Roset PN, Ortuno J, Segura J, Cami J
(1999) Cardiovascular and neuroendocrine effects and pharmacoki-
netics of 3, 4-methylenedioxymethamphetamine in humans. J
Pharmacol Exp Ther 290:136–145
McElrath K (2005) MDMA and sexual behavior: ecstasy users’ percep-
tions about sexuality and sexual risk. Subst Use Misuse 40:1461–
1477
Mithoefer MC, Wagner MT, Mithoefer AT, Jerome I, Doblin R (2010)
The safety and efficacy of ±3,4-methylenedioxymethamphetamine-
assisted psychotherapy in subjects with chronic, treatment-resistant
posttraumatic stress disorder: the first randomized controlled pilot
study. J Psychopharmacol 25:439–452
Muller U, Rowe JB, Rittman T, Lewis C, Robbins TW, Sahakian BJ
(2013) Effects of modafinil on non-verbal cognition, task enjoyment
and creative thinking in healthy volunteers. Neuropharmacology 64:
490–495
Neumann ID,MaloumbyR, Beiderbeck DI, LukasM, Landgraf R (2013)
Increased brain and plasma oxytocin after nasal and peripheral ad-
ministration in rats and mice. Psychoneuroendocrinology 38:1985–
1993
Oehen P, Traber R,Widmer V, Schnyder U (2013) A randomized, controlled
pilot study of MDMA (±3,4-methylenedioxymethamphetamine)-
assisted psychotherapy for treatment of resistant, chronic post-
traumatic stress disorder (PTSD). J Psychopharmacol 27:40–52
Parrott AC, Gibbs A, Scholey AB, King R, Owens K, Swann P, Ogden E,
Stough C (2011) MDMA and methamphetamine: some paradoxical
negative and positive mood changes in an acute dose laboratory
study. Psychopharmacology 215:527–536
Passie T, Hartmann U, Schneider U, Emrich HM, Kruger TH (2005)
Ecstasy (MDMA) mimics the post-orgasmic state: impairment of
sexual drive and function during acute MDMA-effects may be due
to increased prolactin secretion. Med Hypotheses 64:899–903
Persson TJ, Ryder AG, Pfaus JG (2016) Comparing subjective ratings of
sexual arousal and desire in partnered sexual activities from women
of different sexual orientations. Arch Sex Behav 45:1391–1402
Qu WM, Huang ZL, Xu XH, Matsumoto N, Urade Y (2008)
Dopaminergic D1 and D2 receptors are essential for the arousal
effect of modafinil. J Neurosci 28:8462–8469
Randall DC, Shneerson JM, Plaha KK, File SE (2003) Modafinil affects
mood, but not cognitive function, in healthy young volunteers. Hum
Psychopharmacol 18:163–173
Randall DC, Fleck NL, Shneerson JM, File SE (2004) The cognitive-
enhancing properties of modafinil are limited in non-sleep-
deprived middle-aged volunteers. Pharmacol Biochem Behav 77:
547–555
Rawson RA, Washton A, Domier CP, Reiber C (2002) Drugs and sexual
effects: role of drug type and gender. J Subst Abus Treat 22:103–108
Repantis D, Schlattmann P, Laisney O, Heuser I (2010) Modafinil and
methylphenidate for neuroenhancement in healthy individuals: a
systematic review. Pharmacol Res 62:187–206
Rothman RB, BaumannMH, Dersch CM, Romero DV, Rice KC, Carroll
FI, Partilla JS (2001) Amphetamine-type central nervous system
stimulants release norepinephrine more potently than they release
dopamine and serotonin. Synapse 39:32–41
Rowley HL, Kulkarni RS, Gosden J, Brammer RJ, Hackett D, Heal DJ
(2014) Differences in the neurochemical and behavioural profiles of
lisdexamfetamine methylphenidate and modafinil revealed by si-
multaneous dual-probe microdialysis and locomotor activity mea-
surements in freely-moving rats. J Psychopharmacol 28:254–269
Rush CR, Kelly TH, Hays LR, Baker RW, Wooten AF (2002) Acute
behavioral and physiological effects of modafinil in drug abusers.
Behav Pharmacol 13:105–115
Schmeichel BE, Berridge CW (2013) Neurocircuitry underlying the pref-
erential sensitivity of prefrontal catecholamines to low-dose
psychostimulants. Neuropsychopharmacology 38:1079–1084
Schmid Y, Hysek CM, Simmler LD, Crockett MJ, Quednow BB, Liechti
ME (2014) Differential effects of MDMA and methylphenidate on
social cognition. J Psychopharmacol 28:847–856
Schmid Y, Enzler F, Gasser P, Grouzmann E, Preller KH, Vollenweider
FX, Brenneisen R, Muller F, Borgwardt S, Liechti ME (2015a)
Acute effects of lysergic acid diethylamide in healthy subjects.
Biol Psychiatry 78:544–553
Schmid Y, Hysek CM, Preller KH, Bosch OG, Bilderbeck AC, Rogers
RD, Quednow BB, Liechti ME (2015b) Effects of methylphenidate
andMDMAon appraisal of erotic stimuli and intimate relationships.
Eur Neuropsychopharmacol 25:17–25
Scoriels L, Barnett JH, Murray GK, Cherukuru S, Fielding M, Cheng F,
Lennox BR, Sahakian BJ, Jones PB (2011) Effects of modafinil on
emotional processing in first episode psychosis. Biol Psychiatry 69:
457–464
Seibert J, Hysek CM, Penno CA, Schmid Y, Kratschmar DV, Liechti ME,
O d e r m a t t A ( 2 0 1 4 ) A c u t e e f f e c t s o f 3 , 4 -
methylenedioxymethamphetamine and methylphenidate on circulating
steroid levels in healthy subjects. Neuroendocrinology 100:17–25
Seifritz E, Baumann P, Muller MJ, Annen O, Amey M, Hemmeter U,
Hatzinger M, Chardon F, Holsboer-Trachsler E (1996)
478 Psychopharmacology (2018) 235:467–479
Neuroendocrine effects of a 20-mg citalopram infusion in healthy
males: a placebo-controlled evaluation of citalopram as 5-HT func-
tion probe. Neuropsychopharmacology 14:253–263
Semple SJ, Patterson TL, Grant I (2002) Motivations associated with
methamphetamine use among HIV+ men who have sex with men.
J Subst Abus Treat 22:149–156
Simmler LD, Hysek CM, Liechti ME (2011) Sex differences in the effects
of MDMA (ecstasy) on plasma copeptin in healthy subjects. J Clin
Endocrinol Metab 96:2844–2850
Simmler L, Buser T, Donzelli M, Schramm Y, Dieu LH, Huwyler J,
Chaboz S, Hoener M, Liechti ME (2013) Pharmacological charac-
terization of designer cathinones in vitro. Br J Pharmacol 168:458–
470
Simmler LD, Rickli A, Schramm Y, Hoener MC, Liechti ME (2014)
Pharmacological profiles of aminoindanes, piperazines, and
pipradrol derivatives. Biochem Pharmacol 88:237–244
Sommers DK, vanWykM, Snyman JR (1994) Dexfenfluramine-induced
prolactin release as an index of central synaptosomal 5-
hydroxytryptamine during treatment with fluoxetine. Eur J Clin
Pharmacol 46:441–444
Spielberger CD, Gorsuch RC, Lusheme RE (1970) Manual for the Stait
Trait Anxiety Inventory. Consulting Psychologists Press, Palo Alto
Strajhar P, Schmid Y, Liakoni E, Dolder PC, Rentsch KM, Kratschmar
DV, Odermatt A, Liechti ME (2016) Acute effects of lysergic acid
diethylamide on circulating steroid levels in healthy subjects. J
Neuroendocrinol 28:12374
Studerus E, Gamma A, Vollenweider FX (2010) Psychometric evaluation
of the altered states of consciousness rating scale (OAV). PLoS One
5:e12412
Tancer M, Johanson CE (2003) Reinforcing, subjective, and physiologi-
cal effects ofMDMA in humans: a comparison with d-amphetamine
and mCPP. Drug Alcohol Depend 72:33–44
Theall KP, Elifson KW, Sterk CE (2006) Sex, touch, and HIV risk among
ecstasy users. AIDS Behav 10:169–178
Thompson MR, Callaghan PD, Hunt GE, Cornish JL, McGregor IS
(2007) A role for oxytocin and 5-HT1A receptors in the prosocial
effects of 3,4 methylenedioxymethamphetamine (Becstasy^).
Neuroscience 146:509–514
Toledano R, Pfaus J (2006) The Sexual Arousal and Desire Inventory
(SADI): a multidimensional scale to assess subjective sexual arousal
and desire. J Sex Med 3:853–877
Turner DC, Robbins TW, Clark L, Aron AR, Dowson J, Sahakian BJ
(2003) Cognitive enhancing effects of modafinil in healthy volun-
teers. Psychopharmacology 165:260–269
Turner DC, Clark L, Dowson J, Robbins TW, Sahakian BJ (2004)
Modafinil improves cognition and response inhibition in adult atten-
tion-deficit/hyperactivity disorder. Biol Psychiatry 55:1031–1040
Vizeli P, Liechti ME (2017) Safety pharmacology of acute MDMA ad-
ministration in healthy subjects. J Psychopharmacol 31:576–588
Volkow ND, Wang GJ, Fowler JS, Telang F, Jayne M, Wong C (2007)
Stimulant-induced enhanced sexual desire as a potential contribut-
ing factor in HIV transmission. Am J Psychiatry 164:157–160
Vollenweider FX, Gamma A, Liechti ME, Huber T (1998) Psychological
and cardiovascular effects and short-term sequelae of MDMA
( Be c s t a s y ^) i n MDMA-n a i v e h e a l t h y v o l u n t e e r s .
Neuropsychopharmacology 19:241–251
White SR, Obradovic T, Imel KM, Wheaton MJ (1996) The effects of
methylenedioxymethamphetamine (MDMA, Becstasy^) on mono-
aminergic neurotransmission in the central nervous system. Prog
Neurobiol 49:455–479
White TL, Justice AJ, de Wit H (2002) Differential subjective effects of
D-amphetamine by gender, hormone levels and menstrual cycle
phase. Pharmacol Biochem Behav 73:729–741
Wong YN, King SP, LaughtonWB, McCormick GC, Grebow PE (1998)
Single-dose pharmacokinetics of modafinil and methylphenidate
given alone or in combination in healthy male volunteers. J Clin
Pharmacol 38:276–282
Wong YN, Simcoe D, Hartman LN, LaughtonWB, King SP,McCormick
GC, Grebow PE (1999) A double-blind, placebo-controlled,
ascending-dose evaluation of the pharmacokinetics and tolerability
of modafinil tablets in healthymale volunteers. J Clin Pharmacol 39:
30–40
Zemishlany Z, Aizenberg D, Weizman A (2001) Subjective effects of
MDMA (‘ecstasy’) on human sexual function. Eur Psychiatry 16:
127–130
Zerssen DV (1976) Die Beschwerden-Lis te . Münchener
Informationssystem. Psychis, München
Zolkowska D, Jain R, Rothman RB, Partilla JS, Roth BL, Setola V,
Prisinzano TE, Baumann MH (2009) Evidence for the involvement
of dopamine transporters in behavioral stimulant effects of
modafinil. J Pharmacol Exp Ther 329:738–746
Psychopharmacology (2018) 235:467–479 479
